Darunavir is an HIV/ AIDS treatment drug product. Darunavir is used with other medicines line cobicistat or ritonavir. The present objective is to develop and validate the HPLC method for the determination of darunavir in the blood plasma sample. Mobile Phase composed for pH 8.10 buffer (K2HPO4), Methanol and acetonitrile in the ratio of 488:162:350 v/v/v. The diluent is a mixture of water and acetonitrile 40:60 v/v. X-Bridge C18 5µm 4.6x250mm column, wavelength 262 nm, injection volume 20µL, flow rate 1.3 ml/min and column oven temperature 35°C were used. Method validation was performed and results were within the acceptable limits. Results confirmed that the developed method is stability indicating and can be applied to analyze the blood plasma samples.
INTRODUCTION
Darunavir is used as an antiretroviral medication to control HIV / AIDS. This drug is recommended to use with other antiretroviral medicines. Darunavir was innovated by Tibotec at University of Illinois at Chicago [1] [2] . It can be used to control after a needle stick injury. Darunavir is approved in the USA in the year of 2006 and it is listed in WHO essential medicines. Darunavir drug is available in Darunavir/ Cobicistat, Darunavir/ Ritonavir combination single pill [3] [4] . Darunavir is well tolerated by patients however it has side effects like high blood sugar, diabetes, muscle pain, tenderness, abdominal pain, and constipation, vomiting and headache [5] [6] . Darunavir is available in ethanolate form and in the market, it is available in tablets dosage form with 75 mg, 150 mg and 600 mg. Present research work objective was to develop a simple, stability indicating HPLC method for the quantification of darunavir in blood plasma and urine samples. Two known synthetic impurities were considered for the HPLC method. Chemical structure of darunavir and its impurities were represented in [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro [2,3- 
Preparation of Diluted Standard Solution
Weighed and transferred accurately 40mg of Darunavir standard into a 100 mL volumetric flask. 70 mL of diluent added and sonicated to dissolve and mix well. 10 mL of this solution pipetted into 100 mL volumetric flask and made up the volume to 50 mL with diluent and mixed well.
Preparation of Sample Solution
Sample powder equivalent to 40 mg of darunavir weighed and transferred to 100 mL volumetric flask. 70 mL diluent added and sonicated for 30 minutes with intermittent shaking. Diluted up to the mark with diluent and mixed well. 10 ml of solution pipetted and diluted to 100 ml with diluent.
Bioanalytical Sample
The liquid-liquid extraction procedure was used to prepare plasma sample. Darunavir tablets 300mg were used; equivalent to 300mg of Darunavir test sample was spiked into 10ml plasma and stored at 2°C for 1 day. Stored spiked solutions were pull-out from the freezer and allowed reach room temperature. A 0.5ml aliquot was transferred to 10.0 mL polypropylene centrifuge tubes. 5.0 mL of ethyl acetate was used to get the two layers and extraction was completed. Centrifuge tubes were kept on vibramax unit for 15 min. 
RESULTS AND DISCUSSION

Method Development
Literature survey and analytes nature were understood and initial method development were started with phosphate buffer and acetonitrile in the ratio of 60:40; inertsil C18 250mm, 4.6mm; 1.0ml/min flow rate; 20µL injection volume. Impurity-1 and 2 were eluted along with darunavir. Three components UV absorbance was scanned from 200 to 400 nm to select the maximum UV absorbance wavelength. Based on the UV absorbance spectrum for three analytes 267 nm was selected. Figure-2 represented the UV spectrum for darunavir and its impurities. Later we changed the mobile phase ratio with methanol and buffer pH also studied to get the high resolution between darunavir and impurities. Finally, pH8.1 buffer, acetonitrile and methanol mobile phase gave satisfactory results. Final method individual chromatograms were shown in Fig.-3 to 5. Method validation was performed to confirm the method stability indicating property with specificity, precision, accuracy, ruggedness, robustness and linearity.
Specificity
Specificity was evaluated for the interference of blank, placebo and known impurities 1 and 2. Forced degradation studies were performed for acid, base, peroxide, thermal, water and UV light. Blank and placebo and known impurities-1 and 2 were well separated and no interference was observed at the retention time of darunavir. Figure-9 t14 represented the force degradation chromatograms. Table-2 represented the force degradation results and peak purity values. Accuracy Accuracy was evaluated with 3 different concentration levels. A known concentration of sample was spiked to plasma sample and recovery studies were performed. Below Table-5 represented the accuracy results. 
Ruggedness
The ruggedness of the final method was checked with precision test samples. Precision sample-1 and 2 were stored at room temperature and refrigerator. Solutions stability was established for 3 days at room temperature and 5 days for refrigerator conditions. % difference in the assay of darunavir and tailing factor, %RSD was evaluated. Results were tabulated in Table- 
Robustness
The ruggedness of the method was determined by verifying the chromatographic conditions such as flow rate, column temperature, mobile phase pH, and acetonitrile and methanol ratio. Tailing factor and %RSD for 5 standard solutions peak area were calculated and result acceptable (tailing factor not more than 2.0 and %RSD is 2.0%). Results were listed in Table-7 Filter verification was performed for PVDF and NYLON filters. Results were tabulated in Table-8 . 
